India to Canada: Acetaminophen Export Trade Route

To import finished acetaminophen formulations into Canada, the following approvals and registrations are necessary:

• Drug Identification Number (DIN): Each acetaminophen product must obtain a DIN, which signifies that Health Canada has assessed and authorized the product for sale in Canada.

• Drug Establishment Licence (DEL): Importers must hold a valid DEL, authorizing them to import drugs into Canada. This licence ensures compliance with Good Manufacturing Practices (GMP) and other regulatory requirements.

• Submission Format: Applications for product approval should be submitted in the Common Technical Document (CTD) or electronic CTD (eCTD) format, facilitating a standardized review process.

• Approval Timelines: The review period for a New Drug Submission (NDS) or Abbreviated New Drug Submission (ANDS) can vary.

• Product Registration Fees: Health Canada imposes fees for the review of drug submissions and the issuance of DINs.

• GMP Inspection Requirements: Health Canada mandates that foreign manufacturing facilities, including those in India, comply with GMP standards. The foreign manufacturing site must be listed on the importer's DEL. (canada.ca)

Indian manufacturers exporting acetaminophen formulations to Canada must adhere to the following GMP standards:

• GMP Certification: Manufacturers must comply with Health Canada's GMP requirements, which align with international standards to ensure product quality and safety.

• Approved Facilities: Only manufacturing sites that have been inspected and approved by Health Canada are permitted to export to Canada. The foreign manufacturing site must be listed on the importer's DEL. (canada.ca)

• Recent Inspections and Regulatory Actions: Health Canada regularly inspects foreign manufacturing facilities to ensure compliance with GMP standards. Any non-compliance identified during these inspections can lead to regulatory actions, including import restrictions or product recalls. Specific details of recent inspections or actions against Indian pharmaceutical companies are documented in Health Canada's inspection databases.

In the past 18 months, several regulatory developments have impacted Indian pharmaceutical exports to Canada:

• Updated Guidance on Importation: In December 2024, Health Canada released an updated version of the guidance document "Importing and Exporting Health Products for Commercial Use (GUI-0117)," providing clearer instructions on importation requirements and compliance expectations. (canada.ca)

• Enhanced GMP Compliance Measures: As of June 2025, Health Canada intensified its GMP compliance measures, including more frequent inspections of foreign manufacturing sites and stricter enforcement actions for non-compliance.

• Policy Shifts on Labeling Standards: In September 2025, Health Canada revised the "Acetaminophen Labelling Standard," introducing new requirements for labeling to enhance consumer safety and product information clarity. (canada.ca)

These developments underscore Health Canada's commitment to ensuring the safety and efficacy of pharmaceutical products imported into Canada.

The Canadian analgesics market, which includes acetaminophen formulations, has experienced significant growth in recent years. Consumers prefer over-the-counter analgesics like acetaminophen due to their convenience and accessibility. These products are widely available in pharmacies, supermarkets, and convenience stores across the country. Additionally, there is a growing trend towards natural and herbal remedies, as consumers seek alternatives to traditional pain relief medications. This has led to an increase in the demand for products that contain natural ingredients, such as Arnica and Willow Bark.

In late 2022 and early 2023, Canada experienced a significant shortage of acetaminophen products, particularly for infants and children. This shortage was due to unprecedented high demand that began in the summer of 2022 and continued through the cold and flu season. Manufacturers increased production and released 13.9 million units of infant and children's acetaminophen and ibuprofen to the Canadian market between November 2022 and May 2023. Over 4.4 million units of foreign-authorized infant and children's acetaminophen and ibuprofen were also imported into Canada to help augment supplies. By April 2023, adult and children's acetaminophen products were readily available, and the shortage ended. (canada.ca)

Canada relies on both domestic manufacturing and imports to meet its acetaminophen demand. The country imports finished pharmaceutical formulations containing acetaminophen from various countries, including India, to supplement domestic production and ensure a stable supply.

Canada maintains a Most-Favored-Nation (MFN) import duty rate of 0% for HS code 30049069, which includes finished pharmaceutical formulations containing acetaminophen. This reflects Canada's commitment to facilitating access to essential medicines. Additionally, pharmaceutical products are generally exempt from the Goods and Services Tax (GST) in Canada, further reducing the cost burden on imports.

As of March 2026, there is no Free Trade Agreement (FTA) between India and Canada that specifically affects pharmaceutical tariffs. However, the existing 0% MFN tariff rate ensures that imports of acetaminophen formulations from India are not subject to import duties. There are no anti-dumping duties imposed on acetaminophen formulations imported into Canada from India.

India is a significant supplier of finished pharmaceutical formulations containing acetaminophen to Canada. In the most recent trade data, India exported $26.0 million USD worth of these formulations to Canada, accounting for 11.2% of India's total acetaminophen formulation exports, which amounted to $232.0 million USD.

Other major countries supplying acetaminophen formulations to Canada include the United States, China, and various European Union (EU) member states. India's share of Canada's total acetaminophen imports is substantial, reflecting its strong position in the market.

India's pricing for acetaminophen formulations is competitive compared to other suppliers. The country's well-established pharmaceutical manufacturing infrastructure and cost-effective production capabilities enable it to offer attractive pricing. This competitive pricing, combined with the absence of import duties and GST exemptions, makes Indian acetaminophen formulations a favorable option for Canadian importers.

India is a global leader in the production of generic pharmaceuticals, accounting for approximately 60% of the global production volume of solid oral dosage forms as of 2024. This extensive manufacturing capacity enables India to produce large volumes of finished dosage forms containing acetaminophen, including tablets, capsules, and syrups.

The cost structure of Indian pharmaceutical manufacturing is highly competitive, attributed to economies of scale, a skilled workforce, and a well-established supply chain. These factors contribute to the affordability of acetaminophen formulations produced in India.

India's pharmaceutical industry is characterized by a high number of facilities compliant with international quality standards. As of 2024, India maintained 396 facilities registered under the U.S. FDA's Generic Drug User Fee Amendments (GDUFA), the highest number globally. Additionally, numerous Indian manufacturing sites hold WHO-GMP certifications, underscoring their adherence to stringent quality standards.

When comparing acetaminophen formulation exports, India offers a favorable balance of cost and quality. In Q1 2024, the global market for acetaminophen formulations exhibited price fluctuations within a 1-8% quarterly range. China experienced a mildly positive trend due to steady export orders, while India saw a notable decline in prices, influenced by high inventory levels and subdued export momentum. (price-watch.ai)

Quality perception and regulatory acceptance are critical factors in the Canadian market. Indian manufacturers have a strong track record of compliance with international regulatory standards, including approvals from the U.S. FDA and WHO-GMP certifications. This compliance ensures that Indian acetaminophen formulations meet the quality requirements of Health Canada.

Supply reliability is another important consideration. India's extensive manufacturing infrastructure and experience in producing large volumes of generic pharmaceuticals contribute to a stable supply chain for acetaminophen formulations.

The India-Canada supply chain for acetaminophen formulations is robust, supported by India's substantial manufacturing capacity. Leading Indian pharmaceutical companies, such as Granules India and Dr. Reddy's Laboratories, operate multiple facilities dedicated to the production of finished dosage forms. For instance, Dr. Reddy's Laboratories reported 23 manufacturing facilities globally as of March 31, 2024, all compliant with U.S. FDA regulations.

Packaging and cold chain capabilities in India are well-developed, ensuring that acetaminophen formulations are stored and transported under optimal conditions to maintain product integrity.

Regarding regulatory compliance, Indian manufacturers have demonstrated a strong track record. For example, in May 2024, the U.S. FDA completed a routine GMP inspection at Dr. Reddy's formulations manufacturing facilities in Visakhapatnam, resulting in a Voluntary Action Indicated (VAI) classification, indicating compliance with regulatory standards.

While there have been occasional supply disruptions due to factors such as regulatory inspections or global events, Indian manufacturers have generally maintained a reliable supply of acetaminophen formulations. Companies continue to invest in capacity expansion and quality improvements to meet global demand.

For Canadian buyers sourcing acetaminophen formulations from India, the following strategies are recommended:

• Implement a Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply of acetaminophen formulations.

• Understand Minimum Order Quantities (MOQs): Indian suppliers may have varying MOQs based on production capabilities and order sizes. Engaging in direct negotiations will help establish mutually beneficial terms.

• Negotiate Favorable Payment Terms: Common payment terms in India-Canada pharmaceutical trade include letters of credit and advance payments. Understanding and negotiating these terms can optimize cash flow and build trust with suppliers.

• Conduct Thorough Supplier Qualification: Evaluate potential suppliers based on their regulatory compliance history, manufacturing capacity, quality control measures, and past performance in international markets.

• Establish Clear Communication Channels: Maintain regular communication with suppliers to stay informed about production schedules, potential delays, and any regulatory changes that may impact supply.

By adopting these strategies, Canadian buyers can effectively source high-quality acetaminophen formulations from India, ensuring a reliable and cost-effective supply chain.

Cost Estimates and Timeline:

• Audit Visits to India:
• Cost: Approximately $10,000 to $15,000 USD per audit, including travel, accommodation, and professional fees.
• Timeline: Planning and coordination may take 4-6 weeks, with the on-site audit lasting 3-5 days.

By adhering to this comprehensive supplier qualification process, Canadian companies can ensure the quality and regulatory compliance of acetaminophen formulations sourced from Indian manufacturers.